Peter Kolchinsky 8/20/25 Peter Kolchinsky 8/20/25

How GCEA stopped us from sandbagging our pricing and peak sales estimates for Cidara’s flu drug

GCEA shows us how to value a medicine not in terms of what you’d pay for the stock but what society should be willing to pay for the product itself. In this article, we perform GCEA for Cidara’s CD388, an anti-flu drug candidate.

Thomas Culman 11/15/24 Thomas Culman 11/15/24

The way forward for therapeutics value assessment

Last week’s publication in the Forum for Health Economics and Policy of Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices is a watershed moment for the field of health economics and outcomes research.

© Copyright 2001-2025 RA Capital Management, L.P. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.

Tweets by rapport_bio

Science

Policy

Culture

Finance

How GCEA stopped us from sandbagging our pricing and peak sales estimates for Cidara’s flu drug

The way forward for therapeutics value assessment